Trial reportJournal of atherosclerosis and thrombosis2020
The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
Trial report in Journal of atherosclerosis and thrombosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05565976. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- SGLT2 inhibitors are associated with reductions in epicardial adipose tissue volume and thickness: a meta-analysis.International journal of obesity (2005) · 2026Pooled it
- Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post-Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Journal of cardiovascular electrophysiology · 2025Pooled it
- Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis.Cardiovascular diabetology · 2023Pooled it
- Pooled it
- Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.Diabetes, obesity & metabolism · 2025Trial
- Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.Cardiovascular diabetology · 2023Trial
- Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.European heart journal · 2021Trial
- Sex Differences in Antiarrhythmic Effects of Empagliflozin: The EMPA-ICD Trial Subanalysis.JACC. Asia · 2026Article
- From bench to bedside: adipose tissue fibrosis in obesity, anti-diabetic therapies, and bariatric surgery.The Korean journal of internal medicine · 2026Review
- Epicardial adipose tissue in coronary microvascular disease.American heart journal plus : cardiology research and practice · 2026Review
- Epicardial Adipose Tissue: A Potential Target to Improve Left Ventricular Diastolic Dysfunction.Reviews in cardiovascular medicine · 2025Review
- Effect of Dapagliflozin Treatment on Index of Cardiac Electrophysiological Balance in Patients With Heart Failure With Reduced Ejection Fraction.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Article
- Fluctuations of epicardial adipose tissue and cardiovascular health: A useful biomarker? A comprehensive review.Journal of cardiovascular and thoracic research · 2025Review
- The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?Cardiovascular diabetology · 2025Review
- Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias.Journal of cellular physiology · 2025Review
- Addressing Endothelial Dysfunction in Heart Failure: The Role of Endothelial Progenitor Cells and New Treatment Horizons.Cardiac failure review · 2025Review
- Crosstalk between ferroptosis and innate immune in diabetic kidney disease: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.Cardiovascular diabetology · 2024Review
- An enhanced deep learning method for the quantification of epicardial adipose tissue.Scientific reports · 2024Article
- Protective Mechanisms of SGLTi in Ischemic Heart Disease.Journal of cardiovascular translational research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEpicardial adipose tissue (EAT) may be associated with arrhythmogenesis. P-wave indices such as P-wave dispersion and P-wave variation indicated a slowed conduction velocity within the atria. This study investigated the effect of dapagliflozin on EAT volume and P-wave indices.
methodsIn the present ad hoc analysis, 35 patients with type 2 diabetes mellitus and coronary artery disease were classified into dapagliflozin group (n=18) and conventional treatment group (n=17). At baseline, EAT volume, HbA1c and plasma level of tumor necrotic factor-α (TNF-α) levels, echocardiography, and 12-lead electrocardiogram (ECG) were performed. EAT volume was measured using computed tomography. Using 12-lead ECG, P-wave indices were measured.
resultsAt baseline, EAT volumes in the dapagliflozin and conventional treatment groups were 113±20 and 110±27 cm
conclusionDapagliflozin reduced plasma level of TNF-α, EAT volume, and P-wave indices, such as P-wave dispersion. The changes in P-wave indices were especially associated with changes in EAT volume.The number and date of registration: UMIN000035660, 24/Jan/2019.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.